Hallam Georgia World Congress Center Room: B308-309 7:00 – 11:00 am


Recent developments in our knowledge of the immune system, the bone marrow micro-environment and the genetic evolution of MDS are optimizing prognostication and management strategies. Intrinsic and extrinsic factors contributing to disease pathogenesis and influencing therapeutic response will be discussed.


This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.


Upon completion of the educational activity, participants should be able to:

  • Describe the various stages of clonal hematopoietic evolution in the elderly
  • Identify the complex interplay between the MDS clone and its microenvironment
  • Describe molecular background, which plays a role in the dysregulation of the innate and adaptive immune system in MDS
  • Discuss both inherited and acquired genetic factors that contribute to MDS pathogenesis and influence prognosis
  • Describe the various processes of inflammation and oxidative stress that are associated with the development and (vasculitic) symptoms of MDS
  • Utilize objective response predictors and strategies to maximize the successful use of hypomethylating agents
  • Apply the objective prognostic factors and measures to identify the patients most suitable for allogeneic stem cell transplant, which may lead to better outcomes


Stephen Nimer, MD – MDSF Chairman
Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida

Rena Buckstein, MD, FRCPC – Symposium Co-Chair
Director of MDS Research Program and Head of National MDS registry
Head, Hematology Site Group
Odette Cancer Center
Toronto, Canada

Mario Cazzola, MD – Symposium Co-Chair
Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Pavia, Italy

Jude Fitzgibbon, PhD
Professor of Personalised Cancer Medicine
Queen Mary University of London
London, United Kingdom

Rami Komrokji, MD
Leukemia and MDS Section Head
Vice Chair, Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

Shahram Kordasti, MD, PhD
King’s College Hospital and King’s College London
Department of Haematological Medicine
London, United Kingdom

John Koreth, MD, PhD
Associate Professor, Harvard Medical School
Senior Physician, Dana-Farber Cancer Institute
Boston, Massachusetts

Luca Malcovati, MD
Associate Professor of Hematology
University of Pavia
Department of Hematology Oncology & Molecular Medicine
Pavia, Italy

Register Here



IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator


Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here